Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Tredje AP fonden

Tredje AP fonden boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 34.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,176 shares of the medical equipment provider’s stock after purchasing an additional 6,000 shares during the period. Tredje AP fonden’s holdings in Intuitive Surgical were worth $10,310,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. raised its stake in shares of Intuitive Surgical by 5.0% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 18,537 shares of the medical equipment provider’s stock worth $8,246,000 after buying an additional 884 shares in the last quarter. Argent Trust Co grew its holdings in Intuitive Surgical by 11.0% during the second quarter. Argent Trust Co now owns 9,685 shares of the medical equipment provider’s stock worth $4,308,000 after acquiring an additional 962 shares during the period. Mercer Global Advisors Inc. ADV raised its position in Intuitive Surgical by 11.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 45,393 shares of the medical equipment provider’s stock worth $20,172,000 after acquiring an additional 4,694 shares in the last quarter. SYSTM Wealth Solutions LLC lifted its holdings in Intuitive Surgical by 4.8% in the 2nd quarter. SYSTM Wealth Solutions LLC now owns 11,001 shares of the medical equipment provider’s stock valued at $4,894,000 after acquiring an additional 500 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in shares of Intuitive Surgical by 0.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 3,973 shares of the medical equipment provider’s stock valued at $1,767,000 after purchasing an additional 33 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $483.32 on Wednesday. The stock has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39. The business has a 50-day moving average of $465.50 and a two-hundred day moving average of $423.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.18 earnings per share. As a group, research analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ISRG has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Morgan Stanley upped their price target on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Citigroup increased their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insiders Place Their Bets

In other news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the transaction, the insider now directly owns 295 shares in the company, valued at $145,113.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares in the company, valued at $145,113.45. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.